Neuroimaging findings with MDMA/ecstasy: Technical aspects, conceptual issues and future prospects

Journal of Psychopharmacology

Volumn 20, Issue 2, 2006, Pages 164-175

  Reneman, Liesbeth ^a,b   De Win, Maartje M L ^a   Van Den Brink, Wim ^a   Booij, Jan ^a   Den Heeten, Gerard J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

1H MRSpectroscopy; Ecstasy; MDMA; Neuroimaging; Serotonin; SPECT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN TRANSPORTER;

ANIMAL; BRAIN; CELL SURVIVAL; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL ASPECT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BRAIN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RESEARCH DESIGN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33746825174     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106061515     Document Type: Review

References (82)

1. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916
2. Boja J W, McNeill R M, Lewin A H, Abraham P, Carroll F I, Kuhar M J (1992) Selective dopamine transporter inhibition by cocaine analogs. Neuroreport 3: 984-986
3. 125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194: 133-134
4. Boot B P, Mechan A O, McCann U D, Ricaurte G A (2002) MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol 453: 239-244.
5. Retraction in: Ricaurte G A. Euro J Pharmacol (2004) 489: 1.
6. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of 'Ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1199
7. Cassel J C, Riegert C, Rutz S, Koenig J, Rothmaier K, Cosquer B, Lazarus C, Birthelmer A, Jeltsch H, Jones B C, Jackisch R (2005) Ethanol, 3,4- Methylenedioxymethamphetamine (Ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat. Neuropsychopharmacology 30: 1870-1882
8. Chang L, Ernst T, Grob C S, Poland R E (1999) Cerebral 1H-MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users. J Magn Reson Imaging 10: 521-526
9. 125I]ADAM to serotonin transporters in rat brain. Synapse 38: 403-412
10. Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden, L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345
11. Curran H V (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41
12. Daumann J, Fischermann T, Pilatus U, Thron A, Moeller-Hartmann W, Gouzoulis-Mayfrank E (2004) Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci Lett 362: 113-116
13. Dewar K M, Grondin L, Carli M, Lima L, Reader T A (1992) [3H]paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem 58: 250-257
14. Fantegrossi W E, Woolverton W L, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte G A, Woods J H, Winger G (2004) Behavioral and neurochemical consequences of long-term intravenous selfadministration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29: 1270-1281
15. 11C]-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16: 93-103
16. Gamma A, Jerome L, Liechti M E, Sumnall H R (2005) Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend 77: 185-193
17. Gijsman H J, Verkes R J, van Gerven J M A, Cohen A F (1999) MDMA study. Neuropsychopharmacology 21: 597
18. Guardian (2002) Ecstasy not dangerous, say scientists, By Sarah Baseley, health editor. Monday September 2
19. Guimaraes A, Schwartz P, Prakash M R, Carr C A, Berger U V, Jenkins B G, Coyle J T, Gonzalez R G (1995) Quantitative in vivo IH nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience 69: 1095-1101
20. Hatzidimitriou G, McCann U D, Ricaurte G A (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107
21. Heinz A, Jones D W (2000) Serotonin transporters in ecstasy users. Br J Psychiatry 176: 193-195
22. Heinz A, Jones D W, Zajicek K, Gorey J G, Juckel G, Higley J D, Weinberger D R (2004) Depletion and restoration of endogenous monoamines affects beta-CIT binding to serotonin but not dopamine transporters in non-human primates. J Neural Transm Suppl 68: 29-38
23. 11C]AFM. J Cereb Blood Flow Metab 22: 1377-1398
24. Insel T R, Battaglia G, Johannessen J N, Marra S, De Souza E B (1989) 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 49: 713-720
25. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle D D, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521
26. Kish S J, Furukawa Y, Chang L J, Tong J, Ginovart N, Wilson A, Houle S, Meyer J H (2005) Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 32: 123-128
27. Kuikka J T, Ahonen A K (1999) Toxic effect of MDMA on brain serotonin neurons. Lancet 353: 1269
28. Kuikka J T, Tiihonen J, Bergstrom K A, Karhu J, Hartikainen P, Viinamaki H, Lansimies E, Lehtonen J, Hakola P (1995) Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 22: 346-350
29. 123I] β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309
30. Lesch K P, Bengel D, Heils A, Sabol S Z, Greenberg B D, Petri S, Benjamin J, Muller C R, Hamer D H, Murphy D L (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531
31. Lew R, Sabol K E, Chou C, Vosmer G L, Richards J, Seiden L S (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865
32. Liechti M E, Gamma A, Vollenweider F X (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154: 161-168
33. Linnet K, Koed K, Wiborg O, Gregersen N (1995) Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res 697: 251-253
34. McCann U D, Ricaurte G A (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24: 333-336
35. McCann U D, Ridenour A, Shaham Y, Ricaurte G A (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'): a controlled study in humans. Neuropsychopharmacology 10: 129-138
36. McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurones in human beings. Lancet 352: 1433-1437
37. 11)C]DASB. Neuropsychopharmacology 30: 1741-1750
38. Mas M, Farre M, de la Torre R, Roset P N, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136-145
39. Mechan A, Yuan J, Hatzidimitriou G, Irvine R J, McCann U D, Ricaurte G A (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology (in press)
40. Meyer J S, Ali S F (2002) Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Ann N Y Acad Sci 965: 373-380
41. 11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry 57: 102-106
42. Molliver M E, Berger U V, Mamounas L A, Molliver D C, O'Hearn E, Wilson, M A (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600: 649-661
43. Morley K C, Li K M, Hunt G E, Mallet P E, McGregor I S (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('Ecstasy') in rats. Neuropharmacology 46: 954-965
44. Nature 2004 Nature editorial 429: 113. DOI: 10.1038/429113a
45. Newberg A B, Amsterdam J D, Wintering N, Ploessl K, Swanson R L, Shults J, Alavi A (2005) 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46: 973-977
46. 1HMRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci 251: 114-116
47. O'Hearn E, Battaglia G, De Souza E B, Kuhar M J, Molliver M E (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
48. O'Shea E, Granados R, Esteban B, Colado M I, Green A R (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37: 919-926
49. 11C]McN5652. J Nucl Med 41: 1465-1477
50. Peroutka S J (1987) Incidence of recreational use of 3,4- methylenedimethoxymethamphetamine (MDMA, 'ecstasy') on an undergraduate campus. N Engl J Med 317: 1542-1543
51. 123I-β-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med 41: 36-44
52. Ramamoorthy S, Blakely R D (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285: 763-766
53. Reneman L, Majoie C B L M, Flick H, den Heeten G J (2002a) Reduced N-acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethaphetamine ('Ecstasy') users-preliminary results. AJNR Am J Neuroradiol 23: 231-237
54. Reneman L, Schmand B, Bakker O, Schilt T, de Win M M, van den Brink W (2006) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol (in press)
55. Reneman L, Booij J, de Bruin K, de Wolff F A, Gunning W B, den Heeten G J, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869
56. 123I]β-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46: 199-205
57. 123I]β-CIT SPECT study. Psychopharmacology 159: 335-340
58. Ricaurte G A, McCann U D (2001) Assessing long-term effects of MDMA (Ecstasy). Lancet 358: 1831-1832
59. Ricaurte G A, Yuan J, McCann U D (2000) (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10
60. Ricaurte G A, Finnegan K T, Irwin I, Langston J W (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 600: 699-708
61. Ricaurte G A, DeLanney L E, Wiener S G, Irwin I, Langston J W (1988a) 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 474: 359-363
62. Ricaurte G A, Forno L S, Wilson M A, DeLanney L E, Irwin I, Molliver M E, Langston J W (1988b) (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260: 51-55
63. Ricaurte G A, Yuan J, Hatzidimitriou G, Cord B J, McCann U D (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ('ecstasy'). Science 297: 2260-2263
64. Retraction Science (2003) 301: 1479
65. Roiser J P, Cook L J, Cooper J D, Rubinsztein D C, Sahakian B J (2005) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry 162: 609-612
66. Scheffel U, Ricaurte G A (1990) Paroxetine as an in vivo indicator of 3,4- methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomograpy ligand? Brain Res 527: 89-95
67. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse 11: 134-139
68. Scheffel U, Szabo Z, Mathews W B, Finley P A, Dannals R F, Ravert H T, Szabo K, Yuan J, Ricaurte G A (1998) In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29: 183-192
69. Schmidt C J, Taylor V L (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36: 4095-4102
70. Semple D M, Ebmeier K P, Glabus M F, O'Carroll R E, Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69
71. Simmons M L, Frondoza C G, Coyle J T (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45: 37-45
72. Slikker W, Ali S F, Scallet A C, Frith C H, Newport G D, Bailey J R (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 94: 448-457
73. Strauss I, Williamson J M, Bertram E H (1997) Histological and 1H magnetic resonance spectroscopic imaging analysis of quinolinic acidinduced damage to the rat striatum. Magn Res Med 37: 24-33
74. Szabo Z, McCann U D, Wilson A A, Scheffel U, Owonikoko T, Mathews W B, Ravert H T, Hilton J, Dannals R F, Ricaurte G A (2002) Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43: 678-692
75. Swaab D F, Fliers E (1985) A sexually dimorphic nucleus in the human brain. Science 228: 1112-1115
76. Time Magazine (2000) Ecstasy, what does it do to your brain? June 5 155 (23)
77. Urenjak J, Williams S R, Gadian D G, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989
78. Verkes R J, Gijsman H J, Pieters M S, Schoemaker R C, de Visser S, Kuijpers M, Pennings E J, de Bruin D, Van de Wijngaart G, Van Gerven J M, Cohen A F (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153: 196-202
79. 123I]β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 30: 996-1005
80. de Win M M, de Jeu R A, de Bruin K, Habraken J B, Reneman L, Booij J, den Heeten G J (2004) Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol 14: 185-189
81. de Win M M L, Jager G, Vervaeke H, Schilt T, Reneman L, Booij J, Verhulst F C, den Heeten G J, Ramsey N F, Korf D J, van der Brink W (in press) The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int J Methods in Psychiatric Research
82. Zhou F C, Tao-Cheng J H, Segv L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805: 241-254